Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses.

Journal of clinical & cellular immunology

Maker AV, Prabhakar B, Pardiwala K.
PMID: 26618054
J Clin Cell Immunol. 2015 Aug;6(4). doi: 10.4172/2155-9899.1000343. Epub 2015 Jul 22.

Rose Bengal (RB) is a red synthetic dye that was initially used in the garment industry and has been used safely for decades as a corneal stain by ophthalmologists. Antineoplastic properties of RB have also been observed, though the...

Cite
Maker AV, Prabhakar B, Pardiwala K. The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. J Clin Cell Immunol. 2015;6(4)doi: 10.4172/2155-9899.1000343.
Maker, A. V., Prabhakar, B., & Pardiwala, K. (2015). The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. Journal of clinical & cellular immunology, 6(4), . https://doi.org/10.4172/2155-9899.1000343
Maker, Ajay V, et al. "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses." Journal of clinical & cellular immunology vol. 6,4 (2015). doi: https://doi.org/10.4172/2155-9899.1000343
Maker AV, Prabhakar B, Pardiwala K. The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. J Clin Cell Immunol. 2015 Aug;6(4). doi: 10.4172/2155-9899.1000343. Epub 2015 Jul 22. PMID: 26618054; PMCID: PMC4662376.
Copy Download .nbib Format: NLM
Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.

Cell death discovery

Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV.
PMID: 27648301
Cell Death Discov. 2016 Sep 12;2:16067. doi: 10.1038/cddiscovery.2016.67. eCollection 2016.

Colon cancer is a leading cause of cancer-related mortality for which targeted therapy is needed; however, trials using apoptosis-inducing ligand monotherapy to overcome resistance to apoptosis have not shown clinical responses. Since colon cancer cells selectively uptake and rapidly...

Cite
Carr RM, Qiao G, Qin J, et al. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. Cell Death Discov. 2016;2:16067doi: 10.1038/cddiscovery.2016.67.
Carr, R. M., Qiao, G., Qin, J., Jayaraman, S., Prabhakar, B. S., & Maker, A. V. (2016). Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. Cell death discovery, 216067. https://doi.org/10.1038/cddiscovery.2016.67
Carr, Ryan M, et al. "Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis." Cell death discovery vol. 2 (2016): 16067. doi: https://doi.org/10.1038/cddiscovery.2016.67
Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. Cell Death Discov. 2016 Sep 12;2:16067. doi: 10.1038/cddiscovery.2016.67. eCollection 2016. PMID: 27648301; PMCID: PMC5018545.
Copy Download .nbib Format: NLM
Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy.

Open journal of clinical & medical case reports

Bhagwandin SB, Weisenberg ES, Ozer H, Maker AV.
PMID: 26693179
Open J Clin Med Case Rep. 2015;1(3). Epub 2015 Jun 29.

INTRODUCTION: Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare lymphoproliferative hematological disease characterized by binucleated lymphocytes, CD 19CASE PRESENTATION: We present a case of PPBL in a young man with massive splenomegaly that mimicked isolated splenic lymphoma requiring splenectomy...

Cite
Bhagwandin SB, Weisenberg ES, Ozer H, et al. Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy. Open J Clin Med Case Rep. 2015;1(3)
Bhagwandin, S. B., Weisenberg, E. S., Ozer, H., & Maker, A. V. (2015). Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy. Open journal of clinical & medical case reports, 1(3), .
Bhagwandin, Shanel B, et al. "Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy." Open journal of clinical & medical case reports vol. 1,3 (2015).
Bhagwandin SB, Weisenberg ES, Ozer H, Maker AV. Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy. Open J Clin Med Case Rep. 2015;1(3). Epub 2015 Jun 29. PMID: 26693179; PMCID: PMC4675630.
Copy Download .nbib Format: NLM
Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT.

Oncoimmunology

Maker AV.
PMID: 26942091
Oncoimmunology. 2015 Aug 12;5(1):e1069937. doi: 10.1080/2162402X.2015.1069937. eCollection 2016.

Targeted immunotherapy for solid gastrointestinal malignancies is challenging due to a lack of identified tumor antigens. Therefore, a strategy that supports and expands tumor infiltrating lymphocytes in the tumor microenvironment may allow these tumor-reactive T-cells to incite an antitumor...

Cite
Maker AV. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology. 2015;5(1):e1069937doi: 10.1080/2162402X.2015.1069937.
Maker, A. V. (2016). Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology, 5(1), e1069937. https://doi.org/10.1080/2162402X.2015.1069937
Maker, Ajay V. "Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT." Oncoimmunology vol. 5,1 (2016): e1069937. doi: https://doi.org/10.1080/2162402X.2015.1069937
Maker AV. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology. 2015 Aug 12;5(1):e1069937. doi: 10.1080/2162402X.2015.1069937. eCollection 2016. PMID: 26942091; PMCID: PMC4760328.
Copy Download .nbib Format: NLM
Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect.

Translational cancer research

Grippo P, Maker AV.
PMID: 28868241
Transl Cancer Res. 2017 May;6:S585-S586. doi: 10.21037/tcr.2017.05.13.

No abstract available.

Cite
Grippo P, Maker AV. Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect. Transl Cancer Res. 2017;6:S585-S586doi: 10.21037/tcr.2017.05.13.
Grippo, P., & Maker, A. V. (2017). Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect. Translational cancer research, 6S585-S586. https://doi.org/10.21037/tcr.2017.05.13
Grippo, Paul, and Maker, Ajay V. "Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect." Translational cancer research vol. 6 (2017): S585-S586. doi: https://doi.org/10.21037/tcr.2017.05.13
Grippo P, Maker AV. Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect. Transl Cancer Res. 2017 May;6:S585-S586. doi: 10.21037/tcr.2017.05.13. PMID: 28868241; PMCID: PMC5578475.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries